Real-World Effectiveness of Eliglustat in Treatment-Naïve and Switch Patients Enrolled in the International Collaborative Gaucher Group Gaucher Registry.

Like Comment
Eliglustat is a first-line oral therapy for adults with Gaucher disease type 1 (GD1) with extensive, intermediate, or poor CYP2D6-metabolizer phenotypes (90% of patients). We report real-world outcomes after 2 years of eliglustat therapy in the International Collaborative Gaucher Group Gaucher Registry (NCT00358943). As of January 2019, baseline and 2-year data (±1 year) were available for 231 eliglustat-treated GD1 patients: 19 treatment-naïve (0 splenectomized) and 212 ERT patients who switched to eliglustat (36 splenectomized). Most patients (89%) were from the United States, where eliglustat was first approved. In treatment-naïve patients, mean hemoglobin increased from 12.4 to 13.4 g/dL (P=0.004, n=18), mean platelet count increased from 113 to 156 x109/L (P<0.0001, n=17); mean spleen volume decreased from 7.4 to 3.5 multiples of normal (MN) (P=0.02, n=7); mean liver volume remained normal (n=7); median spine Z-score was unchanged (-1.3 to -1.2, n=6). In non-splenectomized switch patients, mean hemoglobin remained stable/non-anemic (n=167); mean platelet count remained stable/normal (n=165); mean spleen volume decreased from 3.3 to 2.8 MN (P=0.0009, n=64); mean liver volume remained normal (n=63); median lumbar spine Z-score improved from -0.7 to -0.4 (P=0.014, n=68). In splenectomized switch patients, mean hemoglobin remained stable/non-anemic (n=31); mean platelet count increased from 297 to 324 x109 /L (non-significant, n=29); mean liver volume remained normal (n=13); median spine Z-score improved from -0.8 to -0.6 (non-significant, n=11). Median chitotriosidase decreased in all groups (P<0.01 for all). These real-world results are consistent with eliglustat clinical trial results demonstrating long-term benefit in treatment-naïve patients and stability in ERT switch patients. This article is protected by copyright. All rights reserved.


Click here to read the full article @ American journal of hematology
Go to the profile of ClinOwl

ClinOwl

The wider, wiser view for healthcare professionals. ClinOwl signposts the latest clinical content from over 100 leading medical journals.
1715 Contributions
1 Followers
0 Following

No comments yet.